NCT04679350View on ClinicalTrials.gov

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

November 30, 2022

Study Completion Date

December 30, 2022

Conditions
COVID-19
Interventions
DRUG

hzVSF-v13

Drug: hzVSF-v13 Dosage form: hzVSF-v13 40mg/mL in a 5mL vial Frequency: Dose at Day 1, 3, 7 Other names: a humanized monoclonal antibody (mAb)

DRUG

Placebo (Normal saline solution)

Dosage form: 0.9% NaCl solution Frequency: Dose at Day 1, 3, 7

Trial Locations (3)

35015

Chungnam National University Hospital, Daejeon

42415

Yeungnam University Medical Center, Daegu

42601

Keimyung University Dongsan Hospital, Daegu

Sponsors

Lead Sponsor

ImmuneMed, Inc.
All Listed Sponsors
lead

ImmuneMed, Inc.

INDUSTRY

NCT04679350 - Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia | Biotech Hunter | Biotech Hunter